Precision medicine is bringing pharma and diagnostics closer together, but there’s still a ways to go before the matchup is fully realized.

New test provided through Infinity BiologiX (IBX) laboratories, powered by Cytox’s genoSCORE polygenic risk score platform, with Vanguard providing medical liaison and customer support available from ...

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...

Clinical trials are critical to the introduction of new drugs, but their success depends on the companies’ ability to get enough patients to volunteer. Recently, drug companies have engaged in ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Modern biologics facilities are expected to span a wide bioreactor capacity range to de-risk scale transitions and maintain regulatory continuity from clinical through commercial supply. FDA’s ...

On January 17 2009, the regulations of Legislative Decree No 1072 regarding the "Pharmaceutical Test Data Protection and other undisclosed data of pharmaceutical products" were published in the ...

- Alva10 joins DXRX global network to enable critical piece of end-to-end solution for developing and commercializing precision medicine diagnostics - Partnership will improve test coverage and ...

The Helical virtual AI lab for pharma, an application layer that turns biological foundation models into decision-ready, ...

Bioreactor portfolios of 1,000–15,000 L (including 5,000 and 10,000 L steps) are positioned to de-risk scale transitions while preserving comparability and regulatory rigor. FDA’s Emerging Technology ...